French study tracks Real-World results of combo therapy for stomach cancer
NCT ID NCT06504615
First seen Apr 04, 2026 · Last updated May 10, 2026 · Updated 6 times
Summary
This study follows 208 adults in France who are already receiving nivolumab combined with chemotherapy as their first treatment for advanced or metastatic stomach, gastroesophageal junction, or esophageal cancers. The goal is to see how long patients live and how the disease responds in everyday medical practice. No new treatments are given; researchers simply observe and collect data.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ESOPHAGEAL SQUAMOUS CELL CARCINOMA (ESCC) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Kappa Santé
Paris, France
-
Local Institution - 0001
Paris, 75002, France
Conditions
Explore the condition pages connected to this study.